BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
08 avr. 2024 07h45 HE
|
BioRestorative Therapies, Inc
— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity — — Patient enrollment expected to be completed in 2024 — ...
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
03 avr. 2024 16h38 HE
|
BioRestorative Therapies, Inc
- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the...
BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City
09 oct. 2023 12h10 HE
|
BioRestorative Therapies, Inc
MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
11 juil. 2023 08h30 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., July 11, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference
01 juin 2023 09h15 HE
|
BioRestorative Therapies, Inc
MELVILLE, NY., June 01, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
24 avr. 2023 07h00 HE
|
BioRestorative Therapies, Inc
--Clinical data from safety run-in scheduled to be released in second half of 2023.— MELVILLE, N.Y., April 24, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or...
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
06 déc. 2022 07h00 HE
|
BioRestorative Therapies, Inc
--Non-Dilutive Grant Funding to Support Development of Brown Adipose-Based Therapeutic Programs Directed at Polycystic Ovary Syndrome -- MELVILLE, N.Y., Dec. 06, 2022 (GLOBE NEWSWIRE) --...
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
05 déc. 2022 07h00 HE
|
BioRestorative Therapies, Inc
-- Intellectual Property Provides a Cell-Based Therapeutic Platform Designed to Target All Avascular Zones-- MELVILLE, N.Y., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
30 juin 2022 07h30 HE
|
BioRestorative Therapies, Inc
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage...
BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program
16 févr. 2022 08h30 HE
|
BioRestorative Therapies, Inc
Notice of Allowance Grants Protection for BioRestorative’s Phase 2 Clinical Program to Treat Chronic Lumbar Disc Disease MELVILLE, N.Y., Feb. 16, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies,...